0%
Print report
Variant interpretation report

FAT1 c.4516C>T, p.Arg1506Cys

NM_005245.4:c.4516C>T NP_005236.2:p.(Arg1506Cys) Missense · exon 8 View identifiers
Classification
Uncertain significance

Variant description:

The FAT1 NM_005245.4:c.4516C>T (NP_005236.2:p.(Arg1506Cys)) missense variant has previously been reported in somatic cancers (COSMIC; COSV71674386, n = 6 times). Based on available guidelines, this variant is considered to be a Variant of Uncertain Significance (VUS).

Five-step scale from benign to pathogenic. This variant is uncertain. Select a step to read what it means.

Uncertain.The recorded classification is uncertain significance.

In plain language

Gene-level background from the recorded interpretation.

About FAT1

FAT1 encodes a large cell-surface protein in the cadherin family that helps cells adhere, communicate, and coordinate their growth and movement during development. It functions as a tumor suppressor by limiting cell-proliferation signals, including WNT and YAP1-related signaling. Loss-of-function changes in FAT1 are associated with multiple cancers, although its effects can vary by cellular context.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is Generic ACMG/AMP 2015 with ClinGen SVI recommendations. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 0 Benign evidence criteria: 0
Pathogenic criteria applied · 0

No pathogenic criterion marked as applied in the recorded assessment.

Benign criteria applied · 0

No benign criterion marked as applied in the recorded assessment.

Recorded classification: Uncertain significance

VUS: no adjudicated criteria were met or applied under the generic ACMG/AMP 2015 fallback combination rules.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

gnomAD v4.1
gnomAD v2.1
Population frequency
1,332 / 1,613,972 alleles

gnomAD v4.1: 1,332 / 1,613,972 alleles. Recorded AF 0.000825293. Recorded homozygote count 0.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 0.000413603; MAF= 0.04136%, 116/280462 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 0.000732772; MAF= 0.07328%, 94/128280 alleles, homozygotes = 0); grpmax FAF= 0.00059964.

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 0.0005972418286458898, 11/18418 alleles, homozygotes = 0).

No screenshot for this evidence
REVEL score
0.341 recorded score

Recorded REVEL score: 0.341. Refer to the recorded PP3/BP4 rationale for interpretation.

No listed criterion applied
ClinVar submissions
6 reported laboratory submissions

6 Uncertain significance. ClinVar API review status: criteria provided, multiple submitters, no conflicts.

Context only ClinVar ↗
Functional evidence
Statement recorded

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
6 recorded samples

This variant has previously been reported in somatic cancers (COSMIC; COSV71674386, n = 6 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under Generic ACMG/AMP 2015 with ClinGen SVI recommendations, with the data and sources behind each one.

28 criteria with recorded statuses: 0 met · 7 not met · 17 not assessed · 4 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

None of PS1, PM1, PM5, PP2, or BP1 can be concluded from the supplied evidence because the required same-residue pathogenic comparators, validated domain or hotspot route, gene-level missense mechanism, or truncating-variant predominance are not established.

No VCEP covers FAT1 in this case; the requested criteria were evaluated under generic ACMG/AMP 2015 definitions.

No exact-variant expert-panel ClinVar Pathogenic/Likely pathogenic or Benign/Likely benign classification was found, so PP5 and BP6 are not met.

FAT1 has no VCEP in this case, so generic ACMG/AMP rules govern.

The variant is missense; PP3 and BP4 therefore use the REVEL path only, with no cross-use of SpliceAI or BayesDel.

REVEL 0.341 is in the gray zone: below all PP3 thresholds and above all BP4 thresholds.

PP3 and BP4 are both applicable but not met; no other criteria were adjudicated.

Not met · 7 · evaluated, threshold not reached

PM2 ACMGNot met: gnomAD v4.1 total AF is 0.000825293, above the generic PM2 supporting cutoff of 0.0001, with 1,332 observed alleles. Details ▾Hide ▴
Reasoning

PM2 is not met at the supplied generic supporting threshold of <=0.0001. The variant is present in gnomAD v4.1 at total AF 0.000825293 and grpmax FAF 0.00099187, and in gnomAD v2.1 at total AF 0.000413603 and grpmax FAF 0.00059964. These are all above 0.0001, and the variant is observed in both datasets with zero homozygotes. Generic ACMG/AMP rules govern because no FAT1 VCEP is present, so the all-comers totals are the default rather than the non-cancer subsets.

Rule
Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium. ... PM2 (supporting): <= 0.0001 — SVI recommendation to downgrade PM2 to Supporting (ClinGen SVI 2020) (PMID:25741868)
Evidence considered
  • gnomAD v4.1 all-comers: AF=0.000825293 (1,332/1,613,972 alleles; 0 homozygotes) and grpmax FAF=0.00099187.
  • gnomAD v2.1 all-comers: AF=0.000413603 (116/280,462 alleles; 0 homozygotes) and grpmax FAF=0.00059964.
  • The supplied generic PM2 calibration threshold is <=0.0001 for supporting evidence (ClinGen SVI 2020 recommendation, identified in the prompt with PMID:25741868).
  • The variant is also present in gnomAD v2.1 non-cancer exomes at AF 0.000396355 (93/234,638 exome alleles; 0 homozygotes), but no VCEP-specific non-cancer source rule governs this generic case.
Sources
PP3 ACMG_2015Not met: missense REVEL 0.341 is below the PP3 supporting threshold of 0.644. Details ▾Hide ▴
Reasoning

The variant is a missense SNV, NM_005245.4:c.4516C>T (p.Arg1506Cys), so the governing generic rule selects the REVEL path only; SpliceAI and BayesDel are not used for PP3/BP4 in this situation. REVEL is 0.341, below the supplied PP3 supporting threshold of >= 0.644 (ClinGen SVI calibration, Pejaver et al. 2022, PMID:36413997), and therefore does not meet PP3 at any strength. The result is not a truncating or splice-region variant, so PP3 is applicable but not met.

Rule
Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.).
Evidence considered
  • Variant consequence: missense_variant, NM_005245.4:c.4516C>T, NP_005236.2:p.(Arg1506Cys); this selects the REVEL-only computational path.
  • Local REVEL predictor lookup reports a score of 0.341 for this variant.
  • The supplied generic ClinGen SVI REVEL calibration sets PP3 supporting at >= 0.644, moderate at >= 0.773, and strong at >= 0.932 (Pejaver et al. 2022, PMID:36413997); 0.341 meets none of these thresholds.
  • SpliceAI max delta 0.01 and BayesDel -0.0289959 were not counted because the governing generic path for a missense variant is REVEL only, and no generic ACMG-strength calibration is established for BayesDel.
Sources
PP5 ACMG_2015Not met: ClinVar reports the exact variant as Uncertain significance in six submissions with zero expert-panel classifications, not Pathogenic or Likely pathogenic. Details ▾Hide ▴
Reasoning

The governing rule concerns a reputable source reporting the exact variant as pathogenic when the underlying evidence is unavailable for independent evaluation. ClinVar variation 597999 reports NM_005245.4:c.4516C>T (p.Arg1506Cys) as Uncertain significance across six laboratory submissions, with zero expert-panel submissions; no exact-variant Pathogenic or Likely pathogenic expert-panel classification is present. Therefore PP5 is not met.

Rule
Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar variation 597999, exact variant NM_005245.4:c.4516C>T (p.Arg1506Cys): Uncertain significance, six submissions, zero expert-panel submissions.
Sources
BA1 ACMGNot met: gnomAD v4.1 grpmax FAF is 0.00099187, far below the generic BA1 threshold of 0.05, using 62,490 observed alleles. Details ▾Hide ▴
Reasoning

BA1 is not met. Under the generic default, BA1 requires a filtering allele frequency of at least 0.05. The relevant grpmax FAF is 0.00099187 in gnomAD v4.1, with the grpmax population containing 62,490 observed alleles; the gnomAD v2.1 grpmax FAF is 0.00059964. Both are far below 0.05. The population sizes exceed the 2,000-observed-allele requirement, and no small-isolate popmax point estimate is being substituted for FAF.

Rule
Allele frequency is above 5% in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium. ... BA1 (stand-alone): >= 0.05 — ACMG/AMP 2015 stand-alone benign allele frequency (PMID:25741868)
Evidence considered
  • gnomAD v4.1 all-comers: total AF 0.000825293 (1,332/1,613,972 alleles; 0 homozygotes); grpmax FAF=0.00099187, with the highest observed population count 67/62,490 alleles.
  • gnomAD v2.1 all-comers: total AF 0.000413603 (116/280,462 alleles; 0 homozygotes); grpmax FAF=0.00059964, with the highest observed population count 94/128,280 alleles.
  • The governing framework is generic ACMG/AMP because no VCEP covers FAT1; therefore the all-comers gnomAD entries are the default population sources rather than the non-cancer subsets.
  • The supplied generic BA1 calibration threshold is >= 0.05 (ACMG/AMP 2015 stand-alone benign allele frequency, PMID:25741868).
Sources
BS1 ACMGNot met: gnomAD v4.1 grpmax FAF is 0.00099187, below the generic BS1 threshold of 0.01, with 62,490 observed alleles. Details ▾Hide ▴
Reasoning

BS1 is not met on the supplied generic frequency threshold. The relevant filtering allele frequency is the grpmax FAF, not the popmax point estimate: gnomAD v4.1 grpmax FAF=0.00099187 and gnomAD v2.1 grpmax FAF=0.00059964, both below the generic BS1 default of 0.01. The v4 grpmax population has 62,490 observed alleles, so this conclusion is not driven by a small isolate group. No disease prevalence, penetrance, or allelic-heterogeneity inputs are supplied for a maximum-credible-frequency calculation that would justify a different per-disorder threshold.

Rule
Allele frequency is greater than expected for the disorder. ... BS1 (strong): >= 0.01 — Generic SVI default; per-gene derivation preferred (Whiffin et al. 2017) (PMID:28518168)
Evidence considered
  • gnomAD v4.1 all-comers: grpmax FAF=0.00099187; highest observed population was Remaining individuals with 67/62,490 alleles and popmax AF 0.00107217, but the point estimate was not used for BS1.
  • gnomAD v2.1 all-comers: grpmax FAF=0.00059964; highest observed population was European (non-Finnish) with 94/128,280 alleles and popmax AF 0.000732772, but the point estimate was not used for BS1.
  • The supplied generic BS1 calibration threshold is >= 0.01; per-gene derivation is preferred (Whiffin et al. 2017, PMID:28518168).
  • Because both filtering AF values are below 0.01, the generic frequency rule is not met; a prevalence/penetrance-based calculation is not needed to overturn this result.
Still missing
  • No disorder-specific prevalence, penetrance, or allelic-heterogeneity inputs are available for a maximum-credible-frequency calculation.
Sources
BP4 ACMG_2015Not met: missense REVEL 0.341 exceeds the BP4 supporting threshold of 0.29, so SpliceAI cannot substitute. Details ▾Hide ▴
Reasoning

The variant is a missense SNV, NM_005245.4:c.4516C>T (p.Arg1506Cys), so the governing generic rule selects the REVEL path only; a clean SpliceAI result cannot substitute for a gray-zone REVEL result. REVEL is 0.341, above the supplied BP4 supporting threshold of <= 0.29, and therefore BP4 is not met at any strength. The variant is within the missense scope of BP4, so this is not_applicable only neither; it is applicable but not met.

Rule
Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc).
Evidence considered
  • Variant consequence: missense_variant, NM_005245.4:c.4516C>T, NP_005236.2:p.(Arg1506Cys); this selects the REVEL-only computational path.
  • Local REVEL predictor lookup reports a score of 0.341 for this variant.
  • The supplied generic ClinGen SVI REVEL calibration sets BP4 supporting at <= 0.29, moderate at <= 0.183, and strong at <= 0.016 (Pejaver et al. 2022, PMID:36413997); 0.341 meets none of these thresholds.
  • SpliceAI max delta 0.01 was not used for BP4 because the variant is missense and the governing rule requires the REVEL path; the gray-zone REVEL result does not permit substitution with SpliceAI.
Sources
BP6 ACMG_2015Not met: ClinVar reports the exact variant as Uncertain significance in six submissions with zero expert-panel classifications, not Benign or Likely benign. Details ▾Hide ▴
Reasoning

The governing rule concerns a reputable source reporting the exact variant as benign when the underlying evidence is unavailable for independent evaluation. ClinVar variation 597999 reports NM_005245.4:c.4516C>T (p.Arg1506Cys) as Uncertain significance across six laboratory submissions, with zero expert-panel submissions; no exact-variant Benign or Likely benign expert-panel classification is present. Therefore BP6 is not met.

Rule
Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar variation 597999, exact variant NM_005245.4:c.4516C>T (p.Arg1506Cys): Uncertain significance, six submissions, zero expert-panel submissions.
Sources

Not assessed · 17 · no assessment recorded

PS1 ACMG_2015Not assessed: no previously established pathogenic variant with the same Arg1506Cys amino-acid change was identified in the supplied evidence. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, NP_005236.2:p.(Arg1506Cys), but the supplied evidence does not identify a previously established pathogenic variant producing the same amino-acid change at residue 1506. ClinVar lists this variant itself as uncertain significance, and no variant-specific paper extraction establishes an equivalent pathogenic protein change. A definitive PS1 assessment therefore requires a curated search for pathogenic Arg1506Cys variants caused by another nucleotide change.

Rule
Same amino acid change as a previously established pathogenic variant regardless of nucleotide change.
Evidence considered
  • The case variant is NM_005245.4:c.4516C>T, NP_005236.2:p.(Arg1506Cys).
  • ClinVar variation 597999 classifies the exact variant as uncertain significance with no expert-panel submission.
  • The PM5 candidate file reports zero collected same-residue candidates and no candidate variants.
Still missing
  • A curated cross-nucleotide search for an established pathogenic FAT1 Arg1506Cys variant is unavailable.
Sources
PS2 ACMG_2015Not assessed: no documented proband de novo observation with confirmed maternity and paternity, disease phenotype, and absent family history. Details ▾Hide ▴
Reasoning

No proband-level de novo observation is documented for FAT1 NM_005245.4:c.4516C>T (p.Arg1506Cys). The available case evidence does not provide parental testing, confirmation of both maternity and paternity, or a documented disease phenotype and absence of family history sufficient to evaluate PS2.

Rule
De novo (both maternity and paternity confirmed) in a patient with the disease and no family history.
Evidence considered
  • The available case records identify the variant as FAT1 NM_005245.4:c.4516C>T (p.Arg1506Cys), but contain no proband-parent trio result, parental-origin statement, or family-history assessment.
  • ClinVar lists the variant as uncertain significance with six submissions and conditions reported as not provided; this does not establish a de novo observation.
Still missing
  • Proband phenotype and disease diagnosis are not documented.
  • Parental testing results and confirmation of both maternity and paternity are not documented.
  • Family history is not documented.
PS3 ACMG_2015Not assessed: no variant-specific validated functional assay or reviewed functional result was available for FAT1 p.Arg1506Cys. Details ▾Hide ▴
Reasoning

No variant-specific validated in vitro or in vivo functional assay was identified for FAT1 NM_005245.4:c.4516C>T (p.Arg1506Cys). OncoKB explicitly reports no variant-specific reviewed functional evidence, and the only extracted paper relevant to the functional theme is the ACMG/AMP standards paper, which does not mention FAT1 or this variant. Therefore, the evidence is insufficient to assess PS3 rather than evidence against a damaging effect.

Rule
Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product.
Evidence considered
  • OncoKB record for FAT1 R1506C states: "OncoKB did not identify variant-specific reviewed functional evidence for this variant" and labels the biological effect as unavailable.
  • PMID:25741868 was reviewed through its extracted finding; it provides general ACMG/AMP standards but does not mention FAT1, c.4516C>T, or p.(R1506C), and provides no variant-specific assay result.
Still missing
  • A validated, reproducible assay directly testing FAT1 p.Arg1506Cys and showing a damaging effect is needed.
Sources
PS4 ACMG_2015Not assessed: PMID:34598035 provides no variant-specific case/control counts, OR, or confidence interval needed to test OR >5.0 with a CI excluding 1.0. Details ▾Hide ▴
Reasoning

The governing rule requires a significantly increased prevalence in affected individuals and, under Note 1, an RR or OR >5.0 with a confidence interval that does not include 1.0. PMID:34598035 was screened because literature_pass.json identified it as a PS4 candidate; its available abstract states that germline and somatic variants were assessed in young-onset head and neck cancer but does not provide variant-specific affected-case and unaffected/control counts, an OR, or a confidence interval for NM_005245.4:c.4516C>T (p.Arg1506Cys). Therefore an OR and 95% CI cannot be computed, and gnomAD population frequency alone is not a case-control comparison.

Rule
The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls. ... Relative risk (RR) or odds ratio (OR), as obtained from case-control studies, is >5.0 and the confidence interval around the estimate of RR or OR does not include 1.0.
Evidence considered
  • PMID:34598035 abstract: the study assessed germline and somatic variants in young-onset head and neck carcinoma, but the available text does not report counts for NM_005245.4:c.4516C>T or a case-control effect estimate.
  • No exact-variant case-control counts were available, so no OR or 95% CI was calculated.
Still missing
  • Variant-specific affected-case and unaffected/control counts or a reported OR/RR with its confidence interval are required.
Sources
PM1 ACMG_2015Not assessed: FAT1 R1506 has no supplied critical-domain evidence, no Cancer Hotspots result, and no demonstrated absence of benign variation. Details ▾Hide ▴
Reasoning

The variant is at FAT1 residue 1506. The case has no VCEP and vcep_materials.json contains no FAT1 domain-table entry, so there is no authoritative approved critical-domain list to test. Cancer Hotspots returned no statistically significant hotspot for FAT1 R1506, while COSMIC reports six somatic observations of the exact variant; the generic PM1 rule requires a mutational hotspot or critical, well-established functional domain without benign variation, and the supplied evidence does not establish either route or the required absence of benign variation.

Rule
Located in a mutational hot spot and/or critical and well-established functional domain (e.g. active site of an enzyme) without benign variation.
Evidence considered
  • vcep_materials.json reports no VCEP and an empty domain_tables object for FAT1.
  • Cancer Hotspots reports no statistically significant hotspot for FAT1 R1506.
  • COSMIC reports the exact variant, COSV71674386, six times in somatic cancers; this is not by itself sufficient for generic PM1.
  • No supplied source establishes that residue 1506 lies in a well-established critical functional domain without benign variation.
Still missing
  • A validated FAT1 functional-domain or mutational-hotspot source and evidence excluding benign variation at the relevant region are unavailable.
Sources
PM3 ACMG_2015Not assessed: no affected-proband observation, pathogenic partner allele, or parental/offspring testing establishes a recessive trans configuration. Details ▾Hide ▴
Reasoning

PM3 cannot be assessed from the available evidence. The case identifies NM_005245.4:c.4516C>T (p.Arg1506Cys) in FAT1, but provides no affected-proband observation, no established recessive disorder context for this interpretation, no pathogenic allele in the same individual, and no parental or offspring testing establishing trans phase. The exact ClinVar record is classified as uncertain significance by six laboratories and its available submission data contain no phase, cis/trans, or affected-proband observations. Additional clinical records and family testing are required before PM3 can be applied.

Rule
For recessive disorders, detected in trans with a pathogenic variant. ... This requires testing of parents (or offspring) to determine phase.
Evidence considered
  • The exact ClinVar record NM_005245.4(FAT1):c.4516C>T (p.Arg1506Cys), Variation ID 597999, has six submissions, all classified as uncertain significance; the available submission records provide no pathogenic partner variant, phase, cis/trans relationship, or affected-proband observation.
  • The case summary identifies FAT1 and the missense variant NM_005245.4:c.4516C>T (NP_005236.2:p.(Arg1506Cys)) but does not provide a recessive disease context, affected proband, or family phase data.
  • Richards et al. 2015 provides the generic ACMG/AMP criterion definitions but no FAT1-specific or variant-specific observations.
Still missing
  • The relevant FAT1 disorder and inheritance mode are not established for this case.
  • No pathogenic or likely pathogenic partner variant is documented in the same individual.
  • No parental or offspring testing establishes phase, specifically trans configuration.
  • No affected-proband clinical observation is documented for this variant pair.
Sources
PM5 ACMG_2015Not assessed: no different missense variant at Arg1506 is established as pathogenic in the supplied evidence. Details ▾Hide ▴
Reasoning

The variant is a missense substitution at Arg1506, so PM5 is applicable in principle. However, the supplied PM5 candidate file contains zero same-residue candidates and no established pathogenic alternate missense change at residue 1506. The exact variant is classified as uncertain significance in ClinVar, which cannot serve as the required pathogenic comparator.

Rule
Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before.
Evidence considered
  • The target protein change is NP_005236.2:p.(Arg1506Cys).
  • The PM5 candidate file reports zero total candidates and zero same-residue candidates.
  • ClinVar variation 597999 classifies the target variant as uncertain significance, not pathogenic.
Still missing
  • A curated search for pathogenic FAT1 alternate missense variants at residue 1506 is unavailable.
Sources
PM6 ACMG_2015Not assessed: no documented assumed de novo observation in a proband with a relevant disease phenotype or reported parental testing. Details ▾Hide ▴
Reasoning

No assumed de novo observation is documented for FAT1 NM_005245.4:c.4516C>T (p.Arg1506Cys). The available case evidence does not identify a proband with a relevant disease phenotype or report parental testing, so PM6 cannot be evaluated even though confirmation of maternity and paternity is not required for this criterion.

Rule
Assumed de novo, but without confirmation of paternity and maternity.
Evidence considered
  • The available case records contain no proband-parent segregation result or statement that the variant was assumed to be de novo.
  • ClinVar lists the variant as uncertain significance with conditions reported as not provided; this does not establish an assumed de novo observation.
Still missing
  • Proband phenotype and disease diagnosis are not documented.
  • An assumed de novo observation is not documented.
  • Parental testing or parental genotype results are not documented.
PP1 ACMG_2015Not assessed: no affected family members or variant-positive meioses are documented to evaluate co-segregation with disease. Details ▾Hide ▴
Reasoning

No affected relatives, family pedigree, variant-positive meioses, or other segregation data are documented for FAT1 NM_005245.4:c.4516C>T (p.Arg1506Cys). Therefore, co-segregation with disease in multiple affected family members cannot be evaluated.

Rule
Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease.
Evidence considered
  • The available case records provide no family pedigree, affected-relative testing, or segregation analysis for this variant.
  • ClinVar conditions are reported as not provided and the submissions do not document co-segregation data.
Still missing
  • Family pedigree and number of affected relatives are not documented.
  • Genotypes and phenotypes of affected family members are not documented.
  • Informative meioses and segregation results are not documented.
PP2 ACMG_2015Not assessed: FAT1 missense mechanism and low benign-missense rate are not jointly established by the supplied evidence. Details ▾Hide ▴
Reasoning

The supplied evidence supports FAT1 as a tumor-suppressor gene with loss-of-function disease context, but it does not establish both PP2 requirements: a low rate of benign missense variation and missense variants as a common disease mechanism. gnomAD shows the target variant is present at AF 0.000825293 in v4.1, but a single-variant frequency does not quantify FAT1's benign missense rate or establish the gene's disease mechanism for missense variation.

Rule
Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.
Evidence considered
  • OncoKB provides gene-level context describing FAT1 as a tumor suppressor inactivated by mutation or deletion, but no variant-specific functional evidence.
  • The gene-level context supports FAT1 loss of function as a disease mechanism, not a common missense mechanism.
  • gnomAD v4.1 reports the target variant at AF 0.000825293; this does not provide the required gene-level benign-missense rate.
Still missing
  • Gene-level benign missense constraint and evidence that missense variation is a common FAT1 disease mechanism are unavailable.
Sources
PP4 ACMG_2015Not assessed: no patient phenotype or family-history information is available to determine whether it is highly specific for a single-gene disease. Details ▾Hide ▴
Reasoning

The governing rule requires a patient phenotype or family history highly specific for a disease with a single genetic etiology. The case evidence supplied for this variant contains no patient phenotype, family history, or disease-specific clinical description that can be evaluated for this requirement.

Rule
Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology.
Still missing
  • Patient phenotype, family history, and the specific disease diagnosis are required.
BS2 Not assessed: gnomAD reports zero homozygotes but does not establish healthy-adult status, inheritance model, or early-age full penetrance for FAT1 disease. Details ▾Hide ▴
Reasoning

BS2 is not assessed. The population data show zero homozygotes, but BS2 requires an observed healthy adult individual in the relevant inheritance state and assumes full penetrance at an early age. The available gnomAD summaries do not establish individual adult health status, the disease inheritance model, or expected age and penetrance for FAT1-related disease; heterozygote presence alone is therefore insufficient.

Rule
BS2
Evidence considered
  • gnomAD v4.1 reports 0 homozygotes among 1,613,972 total observed alleles; gnomAD v2.1 reports 0 homozygotes among 280,462 total observed alleles.
  • The available population summaries do not provide the individual-level clinical status, age-at-observation interpretation, inheritance model, or penetrance required to apply BS2.
Still missing
  • Disease inheritance model, age of onset, and penetrance are not established in the available case evidence.
  • No individual-level evidence confirms that observed carriers were healthy adults at an age sufficient to evaluate the disorder.
Sources
BS3 ACMG_2015Not assessed: no variant-specific validated functional assay or reviewed neutral result was available for FAT1 p.Arg1506Cys. Details ▾Hide ▴
Reasoning

No variant-specific validated in vitro or in vivo functional assay was identified for FAT1 NM_005245.4:c.4516C>T (p.Arg1506Cys). OncoKB explicitly reports no variant-specific reviewed functional evidence, and the only extracted paper relevant to the functional theme is the ACMG/AMP standards paper, which does not mention FAT1 or this variant. Therefore, the evidence is insufficient to assess BS3 rather than evidence that the variant has no damaging effect on protein function or splicing.

Rule
Well-established in vitro or in vivo functional studies show no damaging effect on protein function or splicing.
Evidence considered
  • OncoKB record for FAT1 R1506C states: "OncoKB did not identify variant-specific reviewed functional evidence for this variant" and labels the biological effect as unavailable.
  • PMID:25741868 was reviewed through its extracted finding; it provides general ACMG/AMP standards but does not mention FAT1, c.4516C>T, or p.(R1506C), and provides no variant-specific assay result.
Still missing
  • A validated, reproducible assay directly testing FAT1 p.Arg1506Cys and demonstrating no damaging effect on protein function or splicing is needed.
Sources
BS4 ACMG_2015Not assessed: no tested affected relatives or genotype-negative affected family members are documented to demonstrate lack of segregation. Details ▾Hide ▴
Reasoning

No affected family members who were tested for FAT1 NM_005245.4:c.4516C>T (p.Arg1506Cys) are documented, and no genotype-negative affected relatives or non-segregation events are reported. Lack of segregation therefore cannot be evaluated; the available records also do not permit assessment of phenocopies or multiple pathogenic variants in the family.

Rule
Lack of segregation in affected members of a family.
Evidence considered
  • The available case records contain no family pedigree, affected-relative genotypes, or report of a variant-negative affected relative.
  • ClinVar conditions are reported as not provided and the submissions do not document non-segregation evidence.
Still missing
  • Affected relatives and their clinical phenotypes are not documented.
  • Genotypes of affected relatives are not documented.
  • Potential phenocopies or additional pathogenic familial variants cannot be assessed.
BP1 ACMG_2015Not assessed: FAT1 loss-of-function evidence is present, but predominance of truncating disease variants over missense variants is not established. Details ▾Hide ▴
Reasoning

The variant is missense and the supplied gene-level evidence supports FAT1 loss of function through truncating variants, including a reported homozygous frameshift variant. However, the evidence does not establish that disease-causing FAT1 variants are primarily truncating rather than missense or other variant classes. Therefore the specific BP1 gene-level predominance requirement cannot be confirmed.

Rule
Missense variant in a gene for which primarily truncating variants are known to cause disease.
Evidence considered
  • The gene-level context supports FAT1 loss of function as a germline disease mechanism.
  • PMID:40976965 reports a homozygous FAT1 frameshift variant, p.Val2482AsnfsTer16, associated with glomerulotubular nephropathy and congenital anomalies.
  • One truncating report does not establish that FAT1 disease is primarily caused by truncating variants.
Still missing
  • A comprehensive FAT1 disease-variant spectrum demonstrating that disease is primarily caused by truncating variants is unavailable.
Sources
pvs1_gene_contextPMID:25741868 ↗
BP2 ACMG_2015Not assessed: no evidence shows this variant in trans with a pathogenic dominant- disorder allele or in cis with any pathogenic allele. Details ▾Hide ▴
Reasoning

BP2 cannot be assessed from the available evidence. The case provides no observation of NM_005245.4:c.4516C>T (p.Arg1506Cys) in trans with a pathogenic variant in a fully penetrant dominant disorder and no observation of this variant in cis with a pathogenic variant. The exact ClinVar record is classified as uncertain significance by six laboratories and its available submission data contain no phase, cis/trans, or affected-proband observations. Additional genotype-level phasing or family data are required before BP2 can be applied.

Rule
Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern.
Evidence considered
  • The exact ClinVar record NM_005245.4(FAT1):c.4516C>T (p.Arg1506Cys), Variation ID 597999, has six submissions, all classified as uncertain significance; the available submission records provide no pathogenic partner variant, phase, cis/trans relationship, or affected-proband observation.
  • The case summary identifies FAT1 and the missense variant NM_005245.4:c.4516C>T (NP_005236.2:p.(Arg1506Cys)) but does not provide a dominant-disorder context, affected individual, or family phase data.
  • Richards et al. 2015 provides the generic ACMG/AMP criterion definitions but no FAT1-specific or variant-specific observations.
Still missing
  • No fully penetrant dominant disorder context is established for this case.
  • No pathogenic variant in trans is documented in an affected individual.
  • No pathogenic variant in cis is documented in any individual.
  • No parental, offspring, or molecular phasing data are available.
Sources
BP5 ACMG_2015Not assessed: no affected case is documented with this variant and an independently established alternate molecular basis for disease. Details ▾Hide ▴
Reasoning

The governing rule requires the variant to be found in a case with an alternate molecular basis for disease. The available case evidence does not document an affected case carrying NM_005245.4:c.4516C>T together with an independently established alternate molecular diagnosis. Somatic database presence alone does not establish this BP5 situation.

Rule
Variant found in a case with an alternate molecular basis for disease.
Still missing
  • A case report with the exact variant and a confirmed alternate molecular basis for the phenotype is required.
Not applicable · 4· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 N/ANot applicable: PVS1 requires a null variant (nonsense, frameshift, canonical splice, start-loss or stop-loss), and this is a missense variant. Details ▾Hide ▴
Reasoning

PVS1 (ClinGen SVI PVS1 recommendations, PMC6185798, pvs1_generic_framework) applies only to null variant classes — nonsense, frameshift, canonical ±1/2 splice-consensus, translation-initiation-codon loss, and stop-loss variants — each expected to trigger nonsense-mediated decay or otherwise abolish normal protein function. NM_005245.4:c.4516C>T in FAT1 is a missense substitution predicted to produce NP_005236.2:p.(Arg1506Cys). As a result, no null-variant mechanism (nonsense-mediated decay, truncation, or canonical splice disruption) is triggered by this variant class, so PVS1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PVS1 for FAT1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_null_variant_class
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
PM4 N/ANot applicable: PM4 requires a protein-length change, and this is a missense variant. Details ▾Hide ▴
Reasoning

PM4 (Richards et al. 2015, PMID:25741868) applies to protein length changes: in-frame insertions/deletions in a non-repetitive region, or stop-loss variants that extend the protein past the reference stop codon. NM_005245.4:c.4516C>T in FAT1 is a missense substitution predicted to produce NP_005236.2:p.(Arg1506Cys). As a result, no change in protein length occurs, so there is nothing for this criterion to evaluate, so PM4's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PM4 for FAT1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_stop_loss_or_nonrepeat_indel
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
BP3 N/ANot applicable: BP3 requires an in-frame indel in a repeat region, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP3 (Richards et al. 2015, PMID:25741868) applies to in-frame insertions/deletions located in a repetitive region without a known function. NM_005245.4:c.4516C>T in FAT1 is a missense substitution predicted to produce NP_005236.2:p.(Arg1506Cys). As a result, the variant does not alter protein length within a repeat region, so there is nothing for this criterion to evaluate, so BP3's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP3 for FAT1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_repeat_region_indel
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_005245.4:c.4516C>T in FAT1 is a missense substitution predicted to produce NP_005236.2:p.(Arg1506Cys). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for FAT1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Identifiers

Gene
FAT1
Transcript
NM_005245.4
Coding (HGVS c.)
NM_005245.4:c.4516C>T
Protein (HGVS p.)
NP_005236.2:p.(Arg1506Cys)
GRCh38
chr4:186628571 G>A
GRCh37
chr4:187549725 G>A
Location and type
Exon 8 · missense
ClinVar
597999
COSMIC
COSV71674386

Gene diagram

Every interpreted variant in FAT1, mapped onto the exon structure of NM_005245.4. Select a row to find it on the plot.

FAT1NM_005245.4
Fetching transcript structure from UCSC…
gnomAD v4.1 1,332 / 1,613,972 alleles AF 0.000825 · 0 homozygotes · FAF 0.000992
gnomAD v2.1 116 / 280,462 alleles AF 0.000414 · 0 homozygotes · FAF 0.0006
gnomAD-Canada v1.0 Allele count data not recorded

By genetic ancestry

gnomAD v4.1

AF 0.00083 · 1332 / 1,613,972 alleles · 0 hom · FAF 0.00099
Remaining individuals67 / 62,490 0.0011
European (non-Finnish)1228 / 1,179,896 0.001
Admixed American18 / 60,024 0.0003
African/African American11 / 75,022 0.00015
European (Finnish)3 / 64,010 4.7e-05
South Asian4 / 91,078 4.4e-05
East Asian1 / 44,874 2.2e-05
0 alternate alleles recorded in 3 other groups: Amish, Middle Eastern, Ashkenazi Jewish.

gnomAD v2.1

AF 0.00041 · 116 / 280,462 alleles · 0 hom · FAF 0.0006
European (non-Finnish)94 / 128,280 0.00073
Remaining individuals5 / 7,136 0.0007
Admixed American12 / 35,364 0.00034
African/African American2 / 24,186 8.3e-05
European (Finnish)2 / 25,018 8e-05
South Asian1 / 30,602 3.3e-05
0 alternate alleles recorded in 2 other groups: Ashkenazi Jewish, East Asian.

gnomAD-Canada

AF not recorded · ? / ? alleles

Statements

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 0.000825293; MAF= 0.08253%, 1332/1613972 alleles, homozygotes = 0) and has highest observed frequency in the Remaining individuals population (AF= 0.00107217; MAF= 0.10722%, 67/62490 alleles, homozygotes = 0); grpmax FAF= 0.00099187.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 0.000413603; MAF= 0.04136%, 116/280462 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 0.000732772; MAF= 0.07328%, 94/128280 alleles, homozygotes = 0); grpmax FAF= 0.00059964.

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 0.0005972418286458898, 11/18418 alleles, homozygotes = 0).

Open the gnomAD-Canada detail page →

SpliceAI and Pangolin

SpliceAI acceptor lossat +33 bp
0.010
SpliceAI acceptor gainat -357 bp
0.000
SpliceAI donor lossat -83 bp
0.002
SpliceAI donor gainat -356 bp
0.001
Pangolin splice lossmagnitude shown
-0.015
Pangolin splice gain
0.001

Other predictors

REVEL
0.341
BayesDel
-0.029

How the predictions were used

PP3 ACMG_2015Not met: missense REVEL 0.341 is below the PP3 supporting threshold of 0.644. Details ▾Hide ▴
Reasoning

The variant is a missense SNV, NM_005245.4:c.4516C>T (p.Arg1506Cys), so the governing generic rule selects the REVEL path only; SpliceAI and BayesDel are not used for PP3/BP4 in this situation. REVEL is 0.341, below the supplied PP3 supporting threshold of >= 0.644 (ClinGen SVI calibration, Pejaver et al. 2022, PMID:36413997), and therefore does not meet PP3 at any strength. The result is not a truncating or splice-region variant, so PP3 is applicable but not met.

Rule
Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.).
Evidence considered
  • Variant consequence: missense_variant, NM_005245.4:c.4516C>T, NP_005236.2:p.(Arg1506Cys); this selects the REVEL-only computational path.
  • Local REVEL predictor lookup reports a score of 0.341 for this variant.
  • The supplied generic ClinGen SVI REVEL calibration sets PP3 supporting at >= 0.644, moderate at >= 0.773, and strong at >= 0.932 (Pejaver et al. 2022, PMID:36413997); 0.341 meets none of these thresholds.
  • SpliceAI max delta 0.01 and BayesDel -0.0289959 were not counted because the governing generic path for a missense variant is REVEL only, and no generic ACMG-strength calibration is established for BayesDel.
Sources
BP4 ACMG_2015Not met: missense REVEL 0.341 exceeds the BP4 supporting threshold of 0.29, so SpliceAI cannot substitute. Details ▾Hide ▴
Reasoning

The variant is a missense SNV, NM_005245.4:c.4516C>T (p.Arg1506Cys), so the governing generic rule selects the REVEL path only; a clean SpliceAI result cannot substitute for a gray-zone REVEL result. REVEL is 0.341, above the supplied BP4 supporting threshold of <= 0.29, and therefore BP4 is not met at any strength. The variant is within the missense scope of BP4, so this is not_applicable only neither; it is applicable but not met.

Rule
Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc).
Evidence considered
  • Variant consequence: missense_variant, NM_005245.4:c.4516C>T, NP_005236.2:p.(Arg1506Cys); this selects the REVEL-only computational path.
  • Local REVEL predictor lookup reports a score of 0.341 for this variant.
  • The supplied generic ClinGen SVI REVEL calibration sets BP4 supporting at <= 0.29, moderate at <= 0.183, and strong at <= 0.016 (Pejaver et al. 2022, PMID:36413997); 0.341 meets none of these thresholds.
  • SpliceAI max delta 0.01 was not used for BP4 because the variant is missense and the governing rule requires the REVEL path; the gray-zone REVEL result does not permit substitution with SpliceAI.
Sources
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_005245.4:c.4516C>T in FAT1 is a missense substitution predicted to produce NP_005236.2:p.(Arg1506Cys). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for FAT1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.01). REVEL score = 0.341. BayesDel score = -0.0289959.

2 paper records listed. No publication is explicitly linked to an applied criterion in the recorded metadata. None of the listed paper records explicitly indicates that the variant is named.

Recorded publications

  • Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
    Richards S et al. · 2015
    This paper presents the general ACMG/AMP framework for sequence-variant interpretation and defines evidence categories including PS1, PM1, PM5, PP2, and BP1; it does not mention FAT1, c.4516C>T, or p.(R1506C).
    Does not name this variant
    PMID 25741868 ↗
    Quoted passage
    The variant classification approach described in this paper is meant to be applicable to variants in all Mendelian genes whether identified by single gene tests, multi-gene panels, exome sequencing or genome sequencing.

    Proposed Criteria for Interpretation of Sequence Variants, introductory paragraph

  • Germline variants in DNA repair genes are associated with young-onset head and neck cancer.
    Cury SS et al. · 2021
    The available abstract describes a study of germline and somatic variants in young-onset head and neck carcinoma and was screened as a PS4 candidate, but it does not provide variant-specific case/control counts or an effect estimate for NM_005245.4:c.4516C>T (p.Arg1506Cys).
    Does not name this variant
    PMID 34598035 ↗
    Quoted passage
    Germline and somatic variants were assessed to build a comprehensive genetic influence pattern in HNSCC

    Abstract

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 0.000825293; MAF= 0.08253%, 1332/1613972 alleles, homozygotes = 0) and has highest observed frequency in the Remaining individuals population (AF= 0.00107217; MAF= 0.10722%, 67/62490 alleles, homozygotes = 0); grpmax FAF= 0.00099187.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 0.000413603; MAF= 0.04136%, 116/280462 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 0.000732772; MAF= 0.07328%, 94/128280 alleles, homozygotes = 0); grpmax FAF= 0.00059964.

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 0.0005972418286458898, 11/18418 alleles, homozygotes = 0).

ClinVar

This variant has been reported in ClinVar as Uncertain significance (6 clinical laboratories). (ClinVarID = 597999)

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.01). REVEL score = 0.341. BayesDel score = -0.0289959.

Functional

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has previously been reported in somatic cancers (COSMIC; COSV71674386, n = 6 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.